Elegen has raised $35 million in a Series B funding round led by Triatomic Capital, with participation from GSK, John Ballantyne, and existing investors like Andreessen Horowitz and Agilent Technologies. The funds will be used to expand Elegen’s ENFINIA™ DNA product line and enhance its microfluidics approach for clinical workflows. Peter Zhou from Triatomic Capital will join Elegen’s board. CEO Matthew Hill emphasized the investment's role in advancing DNA synthesis technology.

SAN CARLOS, Calif.--(BUSINESS WIRE)--Elegen, the leader in next-generation DNA synthesis and production, today announced a Series B financing of $35 million led by Triatomic Capital. Also joining the round are strategic investors GSK, which recently entered a collaboration and licensing agreement with Elegen to use their proprietary cell-free DNA manufacturing technology in developing GSK’s vaccines and medicines, and John Ballantyne, co-founder of Aldevron. Elegen’s current investors, including Andreessen Horowitz (a16z Bio + Health), KdT Ventures, 8VC, Digitalis Ventures, ACVC Partners, Alix Ventures, AME Cloud Ventures and Agilent Technologies, also participated. The new funds will accelerate the extension of the company’s rapidly growing ENFINIA™ DNA product line across clinical workflows providing turnkey production of GMP-compliant DNA for clinical development of genetic medicines. “The age of genetic medicines is here, but these powerful modalities require innovative new manufacturing approaches to supply the critical input DNA material for rapid discovery, development and then wide-scale production,” said Matthew Hill, Ph.D., Elegen Founder and CEO. “With this investment, we will continue to push the boundaries of DNA synthesis to accelerate upstream discovery and enable rapid and streamlined deployment of new clinical modalities.”

Elegen, a pioneer in next-generation DNA synthesis and production, has secured $35 million in Series B financing led by Triatomic Capital.